According to preclinical evidence, patients with acquired MET alterations may benefit from combining the ALK selective inhibitor lorlatinib with a MET inhibitor (e.g., capmatinib—particularly in patients with central nervous system disease, savolitinib, and crizotinib) [42]. Here, MET is linked to central nervous system disorder.